354 related articles for article (PubMed ID: 31461270)
1. Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader.
Tovell H; Testa A; Zhou H; Shpiro N; Crafter C; Ciulli A; Alessi DR
ACS Chem Biol; 2019 Sep; 14(9):2024-2034. PubMed ID: 31461270
[TBL] [Abstract][Full Text] [Related]
2. The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour growth.
Bago R; Sommer E; Castel P; Crafter C; Bailey FP; Shpiro N; Baselga J; Cross D; Eyers PA; Alessi DR
EMBO J; 2016 Sep; 35(17):1902-22. PubMed ID: 27481935
[TBL] [Abstract][Full Text] [Related]
3. Phosphoproteomics reveals that the hVPS34 regulated SGK3 kinase specifically phosphorylates endosomal proteins including Syntaxin-7, Syntaxin-12, RFIP4 and WDR44.
Malik N; Nirujogi RS; Peltier J; Macartney T; Wightman M; Prescott AR; Gourlay R; Trost M; Alessi DR; Karapetsas A
Biochem J; 2019 Oct; 476(20):3081-3107. PubMed ID: 31665227
[TBL] [Abstract][Full Text] [Related]
4. Characterization of VPS34-IN1, a selective inhibitor of Vps34, reveals that the phosphatidylinositol 3-phosphate-binding SGK3 protein kinase is a downstream target of class III phosphoinositide 3-kinase.
Bago R; Malik N; Munson MJ; Prescott AR; Davies P; Sommer E; Shpiro N; Ward R; Cross D; Ganley IG; Alessi DR
Biochem J; 2014 Nov; 463(3):413-27. PubMed ID: 25177796
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of activation of SGK3 by growth factors via the Class 1 and Class 3 PI3Ks.
Malik N; Macartney T; Hornberger A; Anderson KE; Tovell H; Prescott AR; Alessi DR
Biochem J; 2018 Jan; 475(1):117-135. PubMed ID: 29150437
[TBL] [Abstract][Full Text] [Related]
6. Feedback Activation of SGK3 and AKT Contributes to Rapamycin Resistance by Reactivating mTORC1/4EBP1 Axis via TSC2 in Breast Cancer.
Wang H; Huang F; Zhang Z; Wang P; Luo Y; Li H; Li N; Wang J; Zhou J; Wang Y; Li S
Int J Biol Sci; 2019; 15(5):929-941. PubMed ID: 31182914
[TBL] [Abstract][Full Text] [Related]
7. Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors.
Sommer EM; Dry H; Cross D; Guichard S; Davies BR; Alessi DR
Biochem J; 2013 Jun; 452(3):499-508. PubMed ID: 23581296
[TBL] [Abstract][Full Text] [Related]
8. Class I PI3-kinase or Akt inhibition do not impair axonal polarization, but slow down axonal elongation.
Diez H; Benitez MJ; Fernandez S; Torres-Aleman I; Garrido JJ; Wandosell F
Biochim Biophys Acta; 2016 Nov; 1863(11):2574-2583. PubMed ID: 27421985
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the structure and regulation of two novel isoforms of serum- and glucocorticoid-induced protein kinase.
Kobayashi T; Deak M; Morrice N; Cohen P
Biochem J; 1999 Nov; 344 Pt 1(Pt 1):189-97. PubMed ID: 10548550
[TBL] [Abstract][Full Text] [Related]
10. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
Ribas R; Pancholi S; Guest SK; Marangoni E; Gao Q; Thuleau A; Simigdala N; Polanska UM; Campbell H; Rani A; Liccardi G; Johnston S; Davies BR; Dowsett M; Martin LA
Mol Cancer Ther; 2015 Sep; 14(9):2035-48. PubMed ID: 26116361
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.
Ksionda O; Mues M; Wandler AM; Donker L; Tenhagen M; Jun J; Ducker GS; Matlawska-Wasowska K; Shannon K; Shokat KM; Roose JP
PLoS One; 2018; 13(5):e0193849. PubMed ID: 29799846
[TBL] [Abstract][Full Text] [Related]
12. Identification, structure modification, and characterization of potential small-molecule SGK3 inhibitors with novel scaffolds.
Gong GQ; Wang K; Dai XC; Zhou Y; Basnet R; Chen Y; Yang DH; Lee WJ; Buchanan CM; Flanagan JU; Shepherd PR; Chen Y; Wang MW
Acta Pharmacol Sin; 2018 Dec; 39(12):1902-1912. PubMed ID: 30038340
[TBL] [Abstract][Full Text] [Related]
13. Cinderella finds her shoe: the first Vps34 inhibitor uncovers a new PI3K-AGC protein kinase connection.
Bilanges B; Vanhaesebroeck B
Biochem J; 2014 Dec; 464(2):e7-10. PubMed ID: 25395352
[TBL] [Abstract][Full Text] [Related]
14. Coordinated regulation of serum- and glucocorticoid-inducible kinase 3 by a C-terminal hydrophobic motif and Hsp90-Cdc37 chaperone complex.
Wang Y; Xu W; Zhou D; Neckers L; Chen S
J Biol Chem; 2014 Feb; 289(8):4815-26. PubMed ID: 24379398
[TBL] [Abstract][Full Text] [Related]
15. Functional role of SGK3 in PI3K/Pten driven liver tumor development.
Cao H; Xu Z; Wang J; Cigliano A; Pilo MG; Ribback S; Zhang S; Qiao Y; Che L; Pascale RM; Calvisi DF; Chen X
BMC Cancer; 2019 Apr; 19(1):343. PubMed ID: 30975125
[TBL] [Abstract][Full Text] [Related]
16. Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways.
Kandil E; Tsumagari K; Ma J; Abd Elmageed ZY; Li X; Slakey D; Mondal D; Abdel-Mageed AB
J Surg Res; 2013 Oct; 184(2):898-906. PubMed ID: 23602735
[TBL] [Abstract][Full Text] [Related]
17. Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1.
Najafov A; Sommer EM; Axten JM; Deyoung MP; Alessi DR
Biochem J; 2011 Jan; 433(2):357-69. PubMed ID: 21087210
[TBL] [Abstract][Full Text] [Related]
18. Discovery of an AKT Degrader with Prolonged Inhibition of Downstream Signaling.
You I; Erickson EC; Donovan KA; Eleuteri NA; Fischer ES; Gray NS; Toker A
Cell Chem Biol; 2020 Jan; 27(1):66-73.e7. PubMed ID: 31859249
[TBL] [Abstract][Full Text] [Related]
19. Role of the Phox homology domain and phosphorylation in activation of serum and glucocorticoid-regulated kinase-3.
Tessier M; Woodgett JR
J Biol Chem; 2006 Aug; 281(33):23978-89. PubMed ID: 16790420
[TBL] [Abstract][Full Text] [Related]
20. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
